Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CLK2 | P49760 | 8/20 | 0.65 |
| ▸ | CLK3 | P49761 | 8/20 | 0.65 |
| ▸ | DYRK1A | Q13627 | 8/20 | 0.65 |
| ▸ | ITK | Q08881 | 9/20 | 0.60 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.58 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.58 |
| ▸ | CDK4 | P11802 | 1/20 | 0.58 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.58 |
| ▸ | CCND1 | P24385 | 1/20 | 0.58 |
| ▸ | CDK2 | P24941 | 1/20 | 0.58 |
| ▸ | CCND3 | P30281 | 1/20 | 0.58 |
| ▸ | KDR | P35968 | 1/20 | 0.58 |
| ▸ | CDK7 | P50613 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18448285 | 0.89 | CLK3 (0.67) | CLK2CLK3DYRK1AITKCDK7 | |
| SCHEMBL20454878 | 0.89 | CLK3 (0.69) | CLK2CLK3DYRK1AITK | |
| SCHEMBL18441732 | 0.87 | CLK2 (0.73) | CLK2CLK3DYRK1ACDK7 | |
| SCHEMBL18482627 | 0.86 | CLK2 (0.52) | CLK2CLK3DYRK1AITKFGFR1 | |
| SCHEMBL18446779 | 0.85 | CLK3 (0.64) | CLK2CLK3DYRK1AITKCHEK1 | |
| SCHEMBL18495485 | 0.85 | CLK2 (0.59) | CLK2CLK3DYRK1AITKFGFR1 | |
| SCHEMBL18446785 | 0.85 | CLK2 (0.62) | CLK2CLK3DYRK1AITKFGFR1 | |
| SCHEMBL20451184 | 0.85 | CLK2 (0.60) | CLK2CLK3DYRK1AITKFGFR1 | |
| SCHEMBL20451154 | 0.84 | CLK2 (0.57) | CLK2CLK3DYRK1AITKFGFR1 | |
| SCHEMBL18445979 | 0.84 | CLK3 (0.66) | CLK2CLK3DYRK1AITKFGFR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180222891-A1 | 3-(1H-INDOL-2-YL)-1H-INDAZOLES AND THERAPEUTIC USES THEREOF | VICKERS-SPLICE CO-INVESTMENT LLC (KY) | 2018-08-09 | — | — | US | claimed |
| WO-2017023986-A1 | 3-(1H-INDOL-2-YL)-1H-INDAZOLES AND THERAPEUTIC USES THEREOF | SAMUMED, LLC (US) | 2017-02-09 | — | — | WO | claimed |
| US-20180222891-A1 | 3-(1H-INDOL-2-YL)-1H-INDAZOLES AND THERAPEUTIC USES THEREOF | VICKERS-SPLICE CO-INVESTMENT LLC (KY) | 2018-08-09 | — | — | US | disclosed |
| US-20180222891-A1 | 3-(1H-INDOL-2-YL)-1H-INDAZOLES AND THERAPEUTIC USES THEREOF | VICKERS-SPLICE CO-INVESTMENT LLC (KY) | 2018-08-09 | — | — | US | disclosed |
| WO-2017023986-A1 | 3-(1H-INDOL-2-YL)-1H-INDAZOLES AND THERAPEUTIC USES THEREOF | SAMUMED, LLC (US) | 2017-02-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180222891-A1 | 3-(1H-INDOL-2-YL)-1H-INDAZOLES AND THERAPEUTIC USES THEREOF | WNT1, WNT3, WNT3A | CLK2 640/4885CLK3 573/4885DYRK1A 585/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.